Press "Enter" to skip to content

The province of Buenos Aires will begin next week to apply third doses and booster vaccines

The Buenos Aires Minister of Health, Nicolas Kreplak, confirmed today that “next week” the Province will begin to vaccinate with third doses to “all immunocompromised people and those who are vaccinated with Sinopharm and are over 50 years.”

“The shifts are sent automatically without the need to re-register,” the official clarified on his Twitter profile. While in radio statements Kreplak said that in a study carried out by his team it was observed that “the Sinopharm vaccine loses a bit of efficacy over the months.”

In this sense, the head of the Buenos Aires health portfolio added: “Sputnik and Johnson & Johnson vaccines continue to have good efficacy over time. With AstraZeneca we will surely ask for a booster dose next year ”.

Shortly after, through a statement, the health portfolio stated that “based on provincial, national and international studies, it was decided to begin with the application of third doses to the immunocompromised population and to those over 50 who were vaccinated with Sinopharm. All the vaccines used in our country have shown high efficacy both to prevent infections and to avoid serious cases and deaths ”.

Along the same lines, it was added: “The Province of Buenos Aires has carried out studies of effectiveness (impact in real life) and immunogenicity (development of antibodies and cellular immunity) of all the vaccines applied, and the results were highly satisfactory.”

In this regard, it was highlighted that “these results made it possible to delay the entry of the Delta variant and advance in progressive openings that led us to be living a context of new normality.” However, at the same time it was stated that “the pandemic did not end and it is essential to continue with care strategies while advancing in new stages of immunization.”

News that is being updated.-

Article Source

Disclaimer: This article is generated from the feed and not edited by our team.